Showing 9401-9410 of 21412 results for "".
Mental Health Implications in Psoriasis
https://reachmd.com/programs/practical-dermatology-il-17-journal-club/mental-health-implications-in-psoriasis/48771/Andrew Blauvelt, MD, MBA, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to talk about how IL-17 inhibition can reduce suicidal ideation and behavior in psoriasis patients, as covered in the Journal of the American Academy of Dermatology article “Mental health outcomes in paShifting the Script: How Inner Dialogue Influences Psoriasis Progress
https://reachmd.com/programs/frontlines-psoriasis/inner-dialogue-psoriasis-progress/39949/A patient’s inner dialogue—especially negative self-talk—can influence their perception of disease, adherence to treatment, and emotional wellbeing. Ryan Quigley sits down with Dr. Michael Greenberg, a dermatologist at the Illinois Dermatology Institute, as he shares observations from his own practiThe Importance of the Atopic Dermatitis Pipeline
https://reachmd.com/videos/dermatology-hub-neuroimmune-network/derm-hub/37148/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, a board-certified dermatologist in San Diego, California, and Director of Clinical Dermatology at Therapeutics Clinical Research, provides an overview of important research underway involving new therapeutics for the treatment of atopPrecision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
https://reachmd.com/clinical-practice/cardiology/precision-medicine-in-obstructive-hcm-care-the-promise-of-cardiac-myosin-inhibitors/48692/Explore the promise of cardiac myosin inhibitors and how they are marking a paradigm shift in obstructive HCM Care.Beyond Anemia: Why Iron Matters in Every Stage of Chronic Kidney Disease
https://reachmd.com/programs/clinicians-roundtable/beyond-anemia-why-iron-matters-in-every-stage-of-chronic-kidney-disease/37221/Iron deficiency in chronic kidney disease (CKD) has traditionally been addressed only in the presence of anemia. But emerging evidence and updated guidelines now support assessing and treating iron deficiency in CKD—even when anemia is not present. Here to share the latest insights from the AmericanGenetic Testing in Pediatrics: Identifying Neurodevelopmental Disorders Early
https://reachmd.com/programs/clinicians-roundtable/genetic-testing-in-pediatrics-identifying-neurodevelopmental-disorders-early/37129/Early genetic evaluation plays a vital role in identifying potential causes of neurodevelopmental disorders and guiding families on next steps, expectations, and recurrence risks. Dr. Jennifer Kalish joins us to share practical insights for recognizing when to initiate testing, selecting theDWTV Extra: Vitiligo Ingenuity Award
https://reachmd.com/videos/dermwire-tv/dwtv-extra-vitiligo-ingenuity-award/37869/Hannah Metheny, a student at the University of Miami Miller School of Medicine, discusses winning an Incyte Ingenuity Award in Vitiligo for the "Barriers and Facilitators to Psychosocial Support as an Integral Aspect of Vitiligo Patient Comprehensive Care" project.Gene Therapy Safety in DMD: How to Identify Common Immune Reactions
https://reachmd.com/programs/neurofrontiers/gene-therapy-safety-in-dmd-how-to-identify-common-immune-reactions/35681/Gene therapy for Duchenne muscular dystrophy (DMD) introduces a micro-dystrophin transgene to support improved protein production, but it’s not without serious risks, including myocarditis, hepatic inflammation, and myositis. Here to help raise awareness of the common immune complications associatedNew Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
https://reachmd.com/programs/frontlines-prostate-cancer/new-frontiers-in-the-imaging-and-treatment-of-advanced-prostate-cancer/32221/From PSMA imaging to precision medicine strategies based on molecular drivers, novel diagnostics and therapies are reshaping the way we care for men with advanced prostate cancer. But despite these advancements, certain challenges and unmet needs remain. Joining Dr. Wayne Kuang to talk about these eInvestigating Inebilizumab for Generalized Myasthenia Gravis: Results from MINT
https://reachmd.com/programs/neurofrontiers/investigating-inebilizumab-for-generalized-myasthenia-gravis-results-from-mint/35495/Recently published in The New England Journal of Medicine, the phase 3 Myasthenia Gravis Inebilizumab Trial (MINT) underscores the potential of inebilizumab as a therapeutic option for patients with generalized myasthenia gravis (gMG). This is based on the efficacy findings that inebilizumab signifi